Clinical Study of Chemogenetic Gene Therapy With AAV for Parkinson's Disease Using Stereotactic Surgery in the Subthalamic Nucleus

Exclusion Criteria

• •Has a past history of brain surgery for Parkinson's disease, such as deep brain stimulation, or other abnormal brain imaging findings;
• •Hamilton Depression Scale score ≥ 20;
• •Hamilton Anxiety Scale score ≥ 14
• •Has a history of brain injury or central nervous system infection;
• •MoCA cognitive impairment score \< 26 points, and MMSE dementia rating scale cognitive impairment score ≤ 20 points;
• •Focal neurological deficits;
• •Evidence of major medical or mental illness, such as dementia, psychosis, history of drug abuse or severe depression;
• •Atypical Parkinson's disease or secondary Parkinson's disease caused by factors such as trauma, brain tumor, infection, cerebrovascular disease, other neurological diseases or drugs, chemicals or toxins;
• •Received other gene or cell therapy drugs;
• •Has a history of malignant tumors, but not including treated carcinoma in situ, or medical conditions that are poorly controlled and may increase the risk of surgery;
• •Has a history of stroke, or obvious cardiovascular diseases, diabetes;
• •Clinically obvious or laboratory-detected infections;
• •Chronic immunosuppressive therapy, including chronic steroids, immunotherapy, cytotoxic therapy and chemotherapy;
• •Coagulation disorders or inability to temporarily stop any anticoagulant or antiplatelet treatment before surgery;
• •Severe liver disease (AST/ALT ≥ 2.5 times the upper limit of normal (ULN));
• •Any factor that may prevent the subject from following the study protocol, including medical or social factors, including geographical inconvenience;
• •Any other situation that the investigator deems unsuitable for participation in this study.